Maverix Medical Gains FDA Clearance for Console-Free Cryo System

The Narwhal system operates without the need for dedicated capital equipment, such as external compressed-gas cylinders or footswitches. Instead, the device uses a self-contained, disposable N₂O cartridge activated by an integrated handle. This design allows clinicians to perform palliative recanalization and tissue biopsies with a 1.3 mm shaft that is compatible with standard bronchoscopes and endoscopes featuring working channels of 2.0 mm or larger.

Key design specifications include an adjustable sheath that allows users to select a freeze zone of 3 mm or 6 mm, providing approximately 160 seconds of total freeze endurance per probe. Clinical interest in this technology follows the FROSTBITE-2 study, which demonstrated a 10% increase in diagnostic yield when using cryoprobes compared to traditional forceps biopsies. Krish Bhadra, a clinical assistant professor at Stanford Medicine, noted that removing the console requirement directly addresses barriers to the wider adoption of cryobiopsy techniques.

Maverix Medical plans to begin broad distribution of the system across the United States in 2027 through its subsidiary, Thoracent. While the device met all safety and performance endpoints during bench and animal testing—including success rates for biopsy weight and histological accessibility—the company reminds clinicians that, as with any cryosurgical intervention, potential risks such as bleeding and pneumothorax remain.